Lakefront Biotherapeutics NV
LKFT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001421876
No open-market purchases or sales by Lakefront Biotherapeutics NV insiders were filed in the last 90 days; 76 institutions reported holding it in 13F filings for Q2 2026, worth $960.3M in total; Greenlight Capital is the only superinvestor holding it.
Other share classesGLPGF
Q3 2025 vs. Q2 2025
How the institutions holding Lakefront Biotherapeutics NV changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Of which not filed for Q3 2025 | Q3 2025 | Change |
|---|---|---|---|---|
| Holders | 85 | 1 | 92 | +8 |
| Shares | 31.7M | 120.0K | 31.4M | −176.5K (−0.6%) |
| Value | $887.2M | $3.36M | $1.09B | +$203.9M (+23.1%) |
1 institution that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (18)
Institutions that held Lakefront Biotherapeutics NV at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Matauro, LLC | 47,536 | $1.65M | 0.26% |
| Marshall Wace, LLP | 38,460 | $1.33M | 0.00% |
| Man Group plc | 36,197 | $1.25M | 0.00% |
| Quadrature Capital Ltd | 26,245 | $909.1K | 0.01% |
| National Bank of Canada | 14,281 | $493.5K | 0.00% |
| HRT Financial LP | 8,697 | $301.0K | 0.00% |
| Brinker Capital Investments, LLC | 7,261 | $251.5K | 0.00% |
| Ascent Group, LLC | 6,313 | $218.7K | 0.01% |
| JustInvest LLC | 6,106 | $211.5K | 0.00% |
| Squarepoint Ops LLC | 6,099 | $211.3K | 0.00% |
| Quadrant Capital Group LLC | 3,880 | $134.4K | 0.00% |
| Simplex Trading, LLC | 254 | $8.00K | 0.00% |
| JPMorgan Chase & Co | 71 | $2.46K | 0.00% |
| Crewe Advisors LLC | 46 | $1.59K | 0.00% |
| Rockefeller Capital Management L.P. | 35 | $1.21K | 0.00% |
| UMA Financial Services, Inc. | 24 | $832 | 0.00% |
| Montag A & Associates Inc | 6 | $208 | 0.00% |
| Farther Finance Advisors, LLC | 1 | $35 | 0.00% |
Sold out (10)
Institutions that held Lakefront Biotherapeutics NV at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Centiva Capital, LP | 94,905 | $2.66M |
| Optiver Holding B.V. | 78,929 | $2.21M |
| Boothbay Fund Management, LLC | 21,866 | $612.0K |
| Engineers Gate Manager LP | 19,990 | $559.5K |
| Susquehanna International Group, LLP | 15,183 | $425.0K |
| Graham Capital Management, L.P. | 8,538 | $239.0K |
| Clear Street Markets LLC | 8,234 | $230.5K |
| Headlands Technologies LLC | 7,973 | $223.2K |
| Caitong International Asset Management Co., Ltd | 90 | $2.52K |
| Bryn Mawr Trust Co | 74 | $2.07K |
Not filed for Q3 2025 yet (1)
Institutions that held Lakefront Biotherapeutics NV at the end of Q2 2025 and haven't filed a 13F for Q3 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Norges Bank | 120,000 | $3.36M |